^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BMS-986408

    i
    Other names: BMS-986408, BMS986408, BMS 986408
    Associations

    News

    Trials
    Company:
    BMS
    Drug class:
    DGKA inhibitor, DGKZ inhibitor
    Related drugs:
    Associations

    News

    Trials
    5ms
    A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=68, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed | N=101 --> 68
    Trial completion • Enrollment change
    |
    BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF mutation
    |
    Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • paclitaxel • pemetrexed • BMS-986408
    over1year
    A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=101, Active, not recruiting, Bristol-Myers Squibb | N=402 --> 101 | Trial primary completion date: Oct 2025 --> Aug 2024
    Enrollment change • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF mutation
    |
    Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • paclitaxel • pemetrexed • BMS-986408
    almost2years
    A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=402, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting | N=113 --> 402 | Trial completion date: Mar 2027 --> Oct 2025 | Trial primary completion date: Mar 2027 --> Oct 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF mutation
    |
    Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • paclitaxel • pemetrexed • BMS-986408
    over3years
    A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=113, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF mutation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • BMS-986408
    over3years
    A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=122, Not yet recruiting, Bristol-Myers Squibb
    New P1/2 trial • Combination therapy
    |
    BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF mutation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • BMS-986408